Vishvas Garg
AbbVie
39 Papers
89 Citations
Vishvas Garg is an academic researcher from AbbVie. The author has contributed to research in topics: Medicine & Adalimumab. The author has an hindex of 12, co-authored 36 publications. Previous affiliations of Vishvas Garg include University of New Mexico & Veterans Health Administration.
Chat about Author
Papers
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.
Beatrice J. Edwards,Andrew D. Bunta,Joseph M. Lane,Clarita Odvina,D. Sudhaker Rao,Dennis W. Raisch,June M. McKoy,Imran M. Omar,Steven M. Belknap,Vishvas Garg,Allison J. Hahr,Athena T. Samaras,Matthew J. Fisher,Dennis P. West,Craig B. Langman,Paula H. Stern +15 more
TL;DR: This study assessed the occurrence of bisphosphonate-associated nonhealing femoral fractures through a review of data from the U.S. FDA Adverse Event Reporting System, published case reports, and international safety efforts to assess whether a safety signal existed.
Life-threatening dermatologic adverse events in oncology.
Alyx C. Rosen,Yevgeniy Balagula,Dennis W. Raisch,Dennis W. Raisch,Vishvas Garg,Vishvas Garg,Beatrice Nardone,Nicole E. Larsen,Jennifer Sorrell,Dennis P. West,Milan J. Anadkat,Mario E. Lacouture +11 more
TL;DR: Proactive pharmacovigilance to detect and define safety signals serves to aid oncology practitioners in the recognition of possible, yet uncommon, serious, and/or life-threatening skin reactions.
Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study.
TL;DR: It is demonstrated that the risk of developing a second IMID is significantly higher for individuals who have already experienced a first IMID in a large and contemporary US claims database.
Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's adverse event reporting system and review of case reports in the literature
Dennis W. Raisch,Vishvas Garg,Rasha M. Arabyat,Xian Shen,Beatrice J. Edwards,Frank H. Miller,June M. McKoy,Beatrice Nardone,Dennis P. West +8 more
TL;DR: Although differences in numbers of reports of anaphylaxis reflect relative utilization rates of the various agents, disproportionality analyses (PRR, EBGM) disclose significant safety signals of anphylaxis associated with most GBCAs.
44
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study.
Filip Van den Bosch,Andrew J. K. Östör,Siegfried Wassenberg,Naijun Chen,Chen Wang,Vishvas Garg,J. Kalabic +6 more
- 01 Jun 2017
TL;DR: In patients with moderate-to-severe RA who initiated ADA, improvements in clinical, functional, and PROs were achieved in real-world settings with significantly greater improvements among PSP users in comparison with PSP non-users.